Phase II Neoadjuvant in Inflammatory Breast Cancer
Status:
Terminated
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn how well lapatinib taken alone, followed
by taking lapatinib with paclitaxel, and then taking lapatinib with 5-fluorouracil,
epirubicin, and cyclophosphamide (FEC75) works to help to control Inflammatory Breast Cancer
(IBC). The safety of this drug combination will also be studied.